It is known that the IL23/17 pathway plays a key role in psoriasis pathogenesis, and treatments against this pathway, such as anti-IL17 (secukinumab), are effective in the treatment of psoriasis.27, 28 Consequently, overexpression of miR-498 may be effective in the treatment of psoriasis through the IL17 pathway. The gene discussed is IL17A; the disease is psoriasis.